Cyclerion Therapeutics, Inc.
CYCN
$3.13
-$0.05-1.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.03M | 875.00K | 93.00K | 81.00K | 1.81M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.03M | 875.00K | 93.00K | 81.00K | 1.81M |
| Cost of Revenue | 519.00K | 348.00K | 56.00K | 36.00K | 56.00K |
| Gross Profit | 506.00K | 527.00K | 37.00K | 45.00K | 1.75M |
| SG&A Expenses | 1.34M | 1.53M | 1.71M | 1.50M | 1.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.86M | 1.88M | 1.77M | 1.54M | 1.30M |
| Operating Income | -838.00K | -1.01M | -1.67M | -1.46M | 502.00K |
| Income Before Tax | -799.00K | -976.00K | -324.00K | -1.43M | 530.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -799.00K | -976.00K | -324.00K | -1.43M | 530.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -799.00K | -976.00K | -324.00K | -1.43M | 530.00K |
| EBIT | -838.00K | -1.01M | -1.67M | -1.46M | 502.00K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.21 | -0.30 | -0.11 | -0.56 | 0.21 |
| Normalized Basic EPS | -0.13 | -0.19 | -0.33 | -0.35 | 0.13 |
| EPS Diluted | -0.21 | -0.30 | -0.11 | -0.56 | 0.21 |
| Normalized Diluted EPS | -0.13 | -0.19 | -0.33 | -0.35 | 0.13 |
| Average Basic Shares Outstanding | 3.81M | 3.23M | 3.07M | 2.56M | 2.54M |
| Average Diluted Shares Outstanding | 3.81M | 3.23M | 3.07M | 2.56M | 2.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |